Posted by Michael Wonder on 22 Nov 2022
Carfilzomib in combination with daratumumab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 November 2022 - NICE is unable to make a recommendation on the use of carfilzomib in combination with daratumumab and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma.
This is because Amgen did not provide an evidence submission.
